gemcitabine has been researched along with iniparib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bradley, C; Koo, IC; O'Shaughnessy, J; Osborne, C; Patt, D; Pippen, JE; Rocha, C; Sherman, BM; Yoffe, M | 1 |
| Sinha, G | 1 |
| Barlesi, F; Besse, B; Cappuzzo, F; Carcereny, E; Felip, E; Ferry, D; Garcia-Ribas, I; Mazieres, J; Novello, S; Reck, M; Santoro, A; Scagliotti, G; Soria, JC; von Pawel, J; Zalcman, G | 1 |
| Azim, HA; de Azambuja, E; Piccart, M; Sonnenblick, A | 1 |
| Carlson, RW; Charpentier, E; Danso, MA; Finn, RS; Garcia-Ribas, I; Hellerstedt, B; Miller, KD; Neubauer, M; O'Shaughnessy, J; Richards, P; Robert, N; Rugo, HS; Saleh, M; Schwartzberg, L; Specht, JM; Winer, EP; Yardley, DA | 1 |
| Abkevich, V; Carlson, RW; Chang, PJ; Dakhil, SR; Flaherty, PJ; Ford, JM; Goldstein, LJ; Haley, B; Hartman, AR; Head, B; Jensen, KC; Kurian, AW; Lipson, JA; Manola, J; Reid, JE; Schackmann, EA; Sparano, JA; Telli, ML; Timms, K; Vinayak, S; Wapnir, IL | 1 |
| Alba, E; Awada, A; Bonnefoi, H; Charpentier, E; Coudert, B; Diéras, V; Emmons, GT; Garcia-Ribas, I; Gligorov, J; Jager, A; Lindeman, GJ; Paridaens, R; Pivot, X; Verweij, J; Zambelli, S | 1 |
| Ambrosio, AJ; Birrer, MJ; Bradley, C; Konstantinopoulos, PA; Krasner, CN; Matulonis, UA; Penson, RT; Whalen, CA | 1 |
1 review(s) available for gemcitabine and iniparib
| Article | Year |
|---|---|
An update on PARP inhibitors--moving to the adjuvant setting.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Benzamides; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Gemcitabine; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors | 2015 |
6 trial(s) available for gemcitabine and iniparib
| Article | Year |
|---|---|
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Carboplatin; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Survival Analysis | 2011 |
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2014 |
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; United States | 2014 |
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; BRCA1 Protein; BRCA2 Protein; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Genomic Instability; Humans; Mastectomy, Segmental; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Recurrence; Treatment Outcome | 2023 |
3 other study(ies) available for gemcitabine and iniparib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bias; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Female; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Research Design; Treatment Failure; Triple Negative Breast Neoplasms | 2014 |